Carregant...

Theranostics in immuno-oncology using nanobody derivatives

Targeted therapy and immunotherapy have become mainstream in cancer treatment. However, only patient subsets benefit from these expensive therapies, and often responses are short‐lived or coincide with side effects. A growing modality in precision oncology is the development of theranostics, as this...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Theranostics
Autors principals: Lecocq, Quentin, De Vlaeminck, Yannick, Hanssens, Heleen, D'Huyvetter, Matthias, Raes, Geert, Goyvaerts, Cleo, Keyaerts, Marleen, Devoogdt, Nick, Breckpot, Karine
Format: Artigo
Idioma:Inglês
Publicat: Ivyspring International Publisher 2019
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6831473/
https://ncbi.nlm.nih.gov/pubmed/31695800
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/thno.34941
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!